Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Madrigal Pharmaceuticals Inc (MDGL)  
$211.32 6.07 (2.96%) as of 4:30 Mon 5/13


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 19,740,000
Market Cap: 4.17(B)
Last Volume: 9,322,967 Avg Vol: 9,297,189
52 Week Range: $120.4 - $292.92
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Diagnostic Substances

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    : 27
Insider 3/6 Months : 27.6
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Co.'s primary product candidate, resmetirom, is being developed as a once-daily oral pill to treat several disease states, including non-alcoholic steatohepatitis, or NASH. Co. has initiated MAESTRO-NASH, a Phase 3 trial in NASH with its once daily, oral thyroid hormone receptor beta selective agonist, resmetirom. Co. has opened for enrollment MAESTRO-NAFLD-1, a Phase 3 clinical study of patients with biopsy-confirmed or presumed NASH recruited from sites in the U.S.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 424,685 424,685 424,685
Total Buy Value $0 $77,751,391 $77,751,391 $77,751,391
Total People Bought 0 1 1 1
Total Buy Transactions 0 10 10 10
Total Shares Sold 252,542 270,142 270,142 339,631
Total Sell Value $62,399,106 $66,219,580 $66,219,580 $85,688,008
Total People Sold 5 7 7 8
Total Sell Transactions 13 21 21 26
End Date 2024-02-11 2023-11-10 2023-05-12 2022-05-12

   
Records found: 413
  Page 5 of 17  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Craves Fred B Director   –       •       •   2019-12-13 4 S $105.47 $126,564,000 I/I (1,200,000) 88,152     -
   Bay City Capital Fund Iv Co Invesment Fund Lp 10% Owner   –       –       •   2019-12-13 4 S $105.47 $126,564,000 I/I (1,200,000) 88,152     -
   Lynch Brian Joseph SVP and General CounselOfficer   •       –      –    2019-04-29 3 IO $0.00 $0 I/I 0 530     -
   Milligan David V Director   –       •      –    2018-11-21 4 S $112.54 $2,250,800 D/D (20,000) 0     -
   Friedman Paul A Chief Executive Officer   •       •      –    2018-11-20 4 B $117.88 $471,520 D/D 4,000 161,128 2.81     -
   Milligan David V Director   –       •      –    2018-11-19 4 S $131.60 $1,316,000 D/D (10,000) 20,000     -
   Craves Fred B Director   –       •       •   2018-11-19 4 B $123.17 $249,387 D/D 2,000 298,067 3.92     -
   Friedman Paul A Chief Executive Officer   •       •      –    2018-11-19 4 B $124.00 $496,000 D/D 4,000 157,128 2.81     -
   Milligan David V Director   –       •      –    2018-11-14 4 OE $16.46 $164,600 D/D 10,000 30,000     -
   Milligan David V Director   –       •      –    2018-09-18 4 OE $9.45 $189,000 D/D 20,000 20,000     -
   Schneebaum Marc R Chief Financial Officer   •       –      –    2018-06-11 4 S $287.46 $2,903,059 D/D (10,099) 41,668     -
   Schneebaum Marc R Chief Financial Officer   •       –      –    2018-06-11 4 OE $61.60 $689,409 D/D 7,957 51,767     -
   Craves Fred B Director   –       •       •   2018-06-11 4 S $287.46 $1,698,314 I/I (5,908) 113,472     -
   Craves Fred B Director   –       •       •   2018-06-11 4 S $287.46 $78,790,486 I/I (274,092) 5,264,382     -
   Taub Rebecca Chief Medical Officer, EVP R&D   •       •      –    2018-06-11 4 S $287.46 $21,135,784 I/I (73,526) 655,540     -
   Bay City Capital Fund Llc Director   –       •       •   2018-06-11 4 S $287.46 $80,488,800 I/I (280,000) 113,472     -
   Friedman Paul A Chief Executive Officer   •       •      –    2018-06-11 4 S $287.46 $21,135,784 I/I (73,526) 655,540     -
   Levy Richard S Director   –       •      –    2017-08-23 4 B $16.08 $32,236 D/D 2,000 9,100 2.39     -
   Levy Richard S Director   –       •      –    2017-08-22 4 B $15.99 $57,209 D/D 3,550 7,100 2.39     -
   Levy Richard S Director   –       •      –    2017-08-21 4 B $15.67 $56,358 D/D 3,550 3,550 2.39     -
   Taub Rebecca Chief Medical Officer, EVP R&D   •       •       •   2016-07-22 4/A A $0.00 $0 D/D 30,626 434,758     -
   Schneebaum Marc R Chief Financial Officer   •       –      –    2016-07-22 4/A A $0.00 $0 D/D 24,501 43,809     -
   Friedman Paul A Chief Executive Officer   •       •      –    2016-07-22 4/A A $0.00 $0 D/D 153,128 153,274     -
   Bay City Capital Fund Iv Co Invesment Fund Lp Director   –       •       •   2016-07-22 3 IO $0.00 $0 I/I 0 5,657,854     -
   Craves Fred B Director   –       •       •   2016-07-22 4 A $0.00 $0 I/I 5,657,854 119,380     -
  413 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 5 of 17
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us